

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Previously Presented) A drug delivery system consisting of one or more compartments and comprising a progestogenic compound dissolved in a thermoplastic polyethylene vinylacetate copolymer whereby,
  - if the delivery system consists of one compartment, the compartment comprises
    - (i) a core of a thermoplastic polyethylene vinylacetate copolymer comprising the progestogenic compound, the progestogenic compound being dissolved in the polyethylene vinylacetate copolymer up to a concentration below the saturation level at 25°C, and an estrogenic compound; and
    - (ii) a skin of a thermoplastic polyethylene vinylacetate copolymer covering the core, the skin being permeable for both compounds;
  - if the delivery system consists of more than one compartment, only one compartment comprises
    - (iii) the progestogenic compound, the progestogenic compound being dissolved in a core of a thermoplastic polyethylene vinylacetate copolymer up to a concentration below the saturation level at 25°C, and an estrogenic compound; and
    - (iv) a skin of a thermoplastic polyethylene vinylacetate copolymer covering the core, the skin being permeable for both compounds.
2. (Original) A drug delivery system according to claim 1, wherein the progestogenic compound is a steroid progestogenic compound and/or the estrogenic compound is a steroid estrogenic compound.

3. (Previously Presented) A drug delivery system according to claim 1, wherein the polyethylene vinylacetate copolymer of the core is a copolymer containing 30 to 50 wt% vinylacetate.
4. (Previously Presented) A drug delivery system consisting of one or more compartments and comprising a progestogenic compound dissolved in a thermoplastic polyethylene vinylacetate copolymer whereby,
  - if the delivery system consists of one compartment, the compartment comprises
    - (i) a core of a thermoplastic polyethylene vinylacetate copolymer, the copolymer containing 30 to 50 wt% vinylacetate, and the core comprising a progestogenic compound, the progestogenic compound being dissolved in the polyethylene vinylacetate copolymer up to a concentration below the saturation level at 25°C, and an estrogenic compound; and
    - (ii) a skin of a thermoplastic polyethylene vinylacetate copolymer covering the core, the copolymer containing 1 to 15 wt% vinylacetate, the skin being permeable for both compounds, and the skin having a thickness in the range of 10 to 110 µm;
  - if the delivery system consists of more than one compartment, only one compartment comprises
    - (iii) the progestogenic compound, the progestogenic compound being dissolved in a core of a thermoplastic polyethylene vinylacetate copolymer up to a concentration below the saturation level at 25°C, the copolymer containing 30 to 50 wt% vinylacetate, and an estrogenic compound; and
    - (iv) a skin of a thermoplastic polyethylene vinylacetate copolymer covering the core, the copolymer containing 1 to 15 wt% vinylacetate, the skin being permeable for both compounds,
- and the skin having a thickness in the range of 10 to 110 µm.
5. (Previously Presented) A drug delivery system consisting of one or more compartments and comprising a progestogenic compound dissolved in a thermoplastic polyethylene vinylacetate copolymer whereby,

- if the delivery system consists of one compartment, the compartment comprises

- (i) a core of a thermoplastic polyethylene vinylacetate copolymer, the copolymer containing 30 to 50 wt% vinylacetate, and the core comprising a progestogenic compound, the progestogenic compound being dissolved in the polyethylene vinylacetate copolymer up to a concentration below the saturation level at 25°C, and an estrogenic compound; and
- (ii) a skin of a thermoplastic polyethylene vinylacetate copolymer covering the core, the copolymer containing 14 to 28 wt% vinylacetate, the skin being permeable for both compounds, and the skin having a thickness of 70 to 250 µm;

- if the delivery system consists of more than one compartment, only one compartment comprises

- (iii) the progestogenic compound, the progestogenic compound being dissolved in a core of a thermoplastic polyethylene vinylacetate copolymer up to a concentration below the saturation level at 25°C, the copolymer containing 30 to 50 wt% vinylacetate, and an estrogenic compound; and
- (iv) a skin of a thermoplastic polyethylene vinylacetate copolymer covering the core, the copolymer containing 14 to 28 wt% vinylacetate, the skin being permeable for both compounds, and the skin having a thickness of 70 to 250 µm.

6. (Previously Presented) A drug delivery system according to claim 1, wherein the progestogenic compound is etonogestrel.
7. (Previously Presented) A drug delivery system according to claim 6 wherein the release on day 21 of etonogestrel of the drug delivery system is 80 µg / day or more.
8. (Previously Presented) A drug delivery system according to claim 1, wherein the estrogenic compound is ethinyl estradiol.
9. (Previously Presented) A drug delivery system according to claim 1, wherein the system is ring-shaped.

10. (Previously Presented) A drug delivery system according to claim 1, wherein the drug delivery system consists of one compartment.
11. (Previously Presented) A drug delivery system according to claim 1, wherein the drug delivery system is a drug delivery system for intravaginal use.
12. (Cancelled)
13. (Previously Presented) A method of manufacturing a drug delivery system according to claim 9 comprising the steps of:
  - (i) producing a medicated homogenous polyethylene vinylacetate copolymer core granulate, comprising a progestogenic and an estrogenic compound;
  - (ii) co-extruding the core granulate with a polyethylene vinylacetate copolymer skin granulate, resulting in a copolymer fiber comprising a core covered by a skin; and
  - (iii) assembling the fibre into a ring.
14. (Original) A method according to claim 13, wherein the core granulate in step (i) is lubricated with a lubricant.
15. (Previously Presented) A contraceptive kit or kit for hormone-replacement therapy comprising the drug delivery system according to claim 1.
16. (Previously Presented) A combination preparation to provide contraception whilst simultaneously to treat a sexually transmitted disease comprising the drug delivery system according to claim 1.
- 17-19. (Cancelled)

20. (New) A drug delivery system according to claim 1, wherein the drug delivery system is physically stable when stored on or above room temperature.
21. (New) A method of contraception in a female patient, the method comprising:
  - (a) positioning a drug delivery system of claim 1 within the vaginal tract of the patient; and
  - (b) retaining the system within the vaginal tract for at least approximately 21 days.